Molecular characterization of PDGFR-α/PDGF-A and c-KIT/SCF in gliosarcomas

Cellular Oncology

Volumn 27, Issue 5-6, 2005, Pages 319-326

  Reis, Rui M ^a   Martins, Albino ^a   Ribeiro, Susana A ^a   Basto, Diana ^a   Longatto Filho, Adhemar ^a,b   Schmitt, Fernando C ^a,c,d   Lopes, José M ^c,d  

^a UNIVERSITY OF MINHO   (Portugal)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c University of Porto   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

BRAF; c Kit; Gliosarcoma; PDGF A; PDGFR ; SCF

Indexed keywords

PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME INHIBITION; EXON; GENE EXPRESSION; GENE INSERTION; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOLECULAR DYNAMICS; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; RNA SPLICING; UPREGULATION;

BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINE, TUMOR; DNA; DNA MUTATIONAL ANALYSIS; ELECTROPHORESIS, AGAR GEL; ENZYME INHIBITORS; GLIOSARCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; MUTATION; PLATELET-DERIVED GROWTH FACTOR; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; STEM CELL FACTOR;

EID: 29244460120     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. B. Actor, J.M. Cobbers, R. Buschges et al., Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components, Genes Chromosomes Cancer 34 (2002), 416-427.
2. L.K. Ashman, The biology of stem cell factor and its receptor C-kit, Int. J. Biochem. Cell Biol. 31 (1999), 1037-1051.
3. D. Basto, V. Trovisco, J.M. Lopes et al., Mutation analysis of B-RAF gene in human gliomas, Acta Neuropathol. (Berl.) 109 (2005), 207-210.
4. G. Bellone, S. Silvestri, E. Artusio et al., Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1, J. Cell Physiol. 172 (1997), 1-11.
5. P. Blume-Jensen and T. Hunter, Oncogenic kinase signalling, Nature 411 (2001), 355-365.
6. R.H. Boerman, K. Anderl, J. Herath et al., The glial and mesenchymal elements of gliosarcomas share similar genetic alterations, J. Neuropathol. Exp. Neurol. 55 (1996), 973-981.
7. J.L. Bos, ras oncogenes in human cancer: a review, Cancer Res. 49 (1989), 4682-4689.
8. E. Buchdunger, C.L. Cioffi, N. Law et al., Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors, J. Pharmacol. Exp. Ther. 295 (2000), 139-145.
9. I. Carvalho, F. Milanezi et al., PDGFR overexpression in breast cancer is associated with tumour progression, Breast Cancer Research (2005), 788-795.
10. S. Carvalho, A.O. Silva, F. Milanezi et al., c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations?, J. Clin. Pathol. 57 (2004), 1075-1079.
11. C.L. Corless, L. McGreevey, A. Haley et al., KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size, Am. J. Pathol. 160 (2002), 1567-1572.
12. D. Cubero-Rego, d.O. Montes, I. Arzuaga-Anderson et al., [Gliosarcoma. Presentation of five cases and review of the literature], Rev. Neurol. 35 (2002), 698-699.
13. H. Davies, G.R. Bignell, C. Cox et al., Mutations of the BRAF gene in human cancer, Nature 417 (2002), 949-954.
14. G.D. Demetri, M. von Mehren, C.D. Blanke et al., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors, N. Engl. J. Med. 347 (2002), 472-480.
15. R.S. DiPaola, W.J. Kuczynski, K. Onodera et al., Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells, Cancer Gene Ther. 4 (1997), 176-182.
16. J. Downward, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer 3 (2003), 11-22.
17. T.P. Fleming, A. Saxena, W.C. Clark et al., Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors, Cancer Res. 52 (1992), 4550-1553.
18. J.A. Fletcher, Role of KIT and platelet-derived growth factor receptors as oncoproteins, Semin. Oncol. 31 (2004), 4-11.
19. A. Guha, K. Dashner, P.M. Black et al., Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop, Int. J. Cancer 60 (1995), 168-173.
20. W. Hamel and M. Westphal, The road less travelled: c-kit and stem cell factor, J. Neurooncol. 35 (1997), 327-333.
21. C. Hartmann, X. Xu, G. Bartels et al., Pdgfr-alpha in 1p/19q LOH oligodendrogliomas, Int. J. Cancer 112 (2004), 1081-1082.
22. M.C. Heinrich, C.D. Blanke, B.J. Druker et al., Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies, J. Clin. Oncol. 20 (2002), 1692-1703.
23. M.C. Heinrich, C.L. Corless, A. Duensing et al., PDGFRA activating mutations in gastrointestinal stromal tumors, Science 299 (2003), 708-710.
24. M. Hermanson, K. Funa, M. Hartman et al., Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops, Cancer Res. 52 (1992), 3213-3219.
25. K. Hibi, T. Takahashi, Y. Sekido et al., Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer, Oncogene 6 (1991), 2291-2296.
26. J.L. Hornick and C.D. Fletcher, Validating immunohistochemical staining for KIT (CD117), Am. J. Clin. Pathol. 119 (2003), 325-327.
27. T. Hunter, Signaling - 2000 and beyond, Cell 100 (2000), 113-127.
28. H. Joensuu, M. Puputti, H. Sihto et al., Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme, J. Pathol. 207 (2005), 224-231.
29. C.B. Knobbe, J. Reifenberger and G. Reifenberger, Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas, Acta Neuropathol. (Berl) 108 (2004), 467-470.
30. G.W. Krystal, S. Honsawek, J. Litz et al., The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth, Clin. Cancer Res. 6 (2000), 3319-3326.
31. G. Lefevre, A.L. Glotin, A. Calipel et al., Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis, J. Biol. Chem. 279 (2004), 31769-31779.
32. M. Lund Johansen, R. Bjerkvig, P.A. Humphrey et al., Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro, Cancer Res. 50 (1990), 6039-6044.
33. R. Matsuda, T. Takahashi, S. Nakamura et al., Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues, Am. J. Pathol. 142 (1993), 339-346.
34. G.A. McArthur, G.D. Demetri, A. van Oosterom et al., Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225, J. Clin. Oncol. 23 (2005), 866-873.
35. M. Nister, T.A. Libermann, C. Betsholtz et al., Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines, Cancer Res. 48 (1988), 3910-3918.
36. H. Ohgaki, W. Biernat, R. Reis, M. Hegi and P. Kleihues, Gliosarcoma, in: Pathology and Genetics of Tumours of the Nervous System, P. Kleihues and W.K. Cavenee, eds, IARC Press, Lyon, 2000.
37. K. Pietras, T. Sjoblom, K. Rubin et al., PDGF receptors as cancer drag targets, Cancer Cell 3 (2003), 439-443.
38. R.M. Reis, D. Konu-Lebleblicioglu, J.M. Lopes et al., Genetic profile of gliosarcomas, Am. J. Pathol. 156 (2000), 425-132.
39. W.D. Richardson, N. Pringle, M.J. Mosley et al., A role for platelet-derived growth factor in normal gliogenesis in the cental nervous system, Cell 53 (1988), 309-319.
40. L.F. Sheu, W.C. Lee, H.S. Lee et al., Co-expression of c-kit and stem cell factor in primary and metastatic nasopharyngeal carcinomas and nasopharyngeal epithelium, J. Pathol. (2005).
41. H. Sihto, M. Sarlomo-Rikala, O. Tynninen et al., KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors, J. Clin. Oncol. 23 (2005), 49-57.
42. M. Stanulla, K. Welte, M.R. Hadam et al., Coexpression of stem cell factor and its receptor c-Kit in human malignant glioma cell lines, Acta Neuropathol. (Berl.) 89 (1995), 158-165.
43. A.T. van Oosterom, I. Judson, J. Verweij et al., Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study, Lancet 358 (2001), 1421-1423.
44. G. Vlahovic and J. Crawford, Activation of tyrosine kinases in cancer, Oncologist 8 (2003), 531-538.
45. P.T. Wan, M.J. Garnett, S.M. Roe et al., Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell 116 (2004), 855-867.
46. P.T. Went, S. Dirnhofer, M. Bundi et al., Prevalence of KIT expression in human tumors, J. Clin. Oncol. 22 (2004), 4514-4522.
47. P.T. Went, S. Dirnhofer, M. Bundi et al., Prevalence of KIT expression in human tumors, J. Clin. Oncol. 22 (2004), 4514-4522.
48. B. Westermark, C.H. Heldin and M. Nister, Platelet-derived growth factor in human glioma, Glia 15 (1995), 257-263.